Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both

Hanna I. Hyry, Jonathan C. P. Roos

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The English High Court recently dismissed the Bayer pharmaceutical company’s challenge against a regional clinical commissioning group’s policy allowing NHS Trusts to use a cheaper, but unlicensed, alternative to a sight preserving eye treatment. This makes sober reading for companies marketing “on-label” sales of medicines which are more expensive than off-label or unlicensed alternatives. Unsurprisingly, Bayer has sought to appeal the judgement. The Court has also created legal uncertainty for the NHS: the test for lawfulness is shifted from the Clinical Commission Groups and their policies to individual trusts which must ensure that every unlicensed use is lawful. This could generate legal action against NHS Trusts and ironically drive up costs for the public purse. What is clear is that the Court’s conclusions were heavily influenced by fiscal constraints which it accepted as a legitimate counterweight to the commercial interests of pharmaceutical companies. It also appears to establish in law the duty for doctors to have concern for the wider societal costs of prescribed treatments. This article summarises this complex judgement and offers advice for navigating the increasing focus on limited budgets, both for companies and physicians.
Original languageEnglish
JournalEye (Basingstoke)
DOIs
Publication statusE-pub ahead of print - 2018
Externally publishedYes

Cite this

@article{7113dd6ea5fa4e23bd27f20f4cfbf3f1,
title = "Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both",
abstract = "The English High Court recently dismissed the Bayer pharmaceutical company’s challenge against a regional clinical commissioning group’s policy allowing NHS Trusts to use a cheaper, but unlicensed, alternative to a sight preserving eye treatment. This makes sober reading for companies marketing “on-label” sales of medicines which are more expensive than off-label or unlicensed alternatives. Unsurprisingly, Bayer has sought to appeal the judgement. The Court has also created legal uncertainty for the NHS: the test for lawfulness is shifted from the Clinical Commission Groups and their policies to individual trusts which must ensure that every unlicensed use is lawful. This could generate legal action against NHS Trusts and ironically drive up costs for the public purse. What is clear is that the Court’s conclusions were heavily influenced by fiscal constraints which it accepted as a legitimate counterweight to the commercial interests of pharmaceutical companies. It also appears to establish in law the duty for doctors to have concern for the wider societal costs of prescribed treatments. This article summarises this complex judgement and offers advice for navigating the increasing focus on limited budgets, both for companies and physicians.",
author = "Hyry, {Hanna I.} and Roos, {Jonathan C. P.}",
year = "2018",
doi = "10.1038/s41433-018-0280-3",
language = "English",
journal = "Eye (Basingstoke)",
issn = "0950-222X",
publisher = "Nature Publishing Group",

}

Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both. / Hyry, Hanna I.; Roos, Jonathan C. P.

In: Eye (Basingstoke), 2018.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both

AU - Hyry, Hanna I.

AU - Roos, Jonathan C. P.

PY - 2018

Y1 - 2018

N2 - The English High Court recently dismissed the Bayer pharmaceutical company’s challenge against a regional clinical commissioning group’s policy allowing NHS Trusts to use a cheaper, but unlicensed, alternative to a sight preserving eye treatment. This makes sober reading for companies marketing “on-label” sales of medicines which are more expensive than off-label or unlicensed alternatives. Unsurprisingly, Bayer has sought to appeal the judgement. The Court has also created legal uncertainty for the NHS: the test for lawfulness is shifted from the Clinical Commission Groups and their policies to individual trusts which must ensure that every unlicensed use is lawful. This could generate legal action against NHS Trusts and ironically drive up costs for the public purse. What is clear is that the Court’s conclusions were heavily influenced by fiscal constraints which it accepted as a legitimate counterweight to the commercial interests of pharmaceutical companies. It also appears to establish in law the duty for doctors to have concern for the wider societal costs of prescribed treatments. This article summarises this complex judgement and offers advice for navigating the increasing focus on limited budgets, both for companies and physicians.

AB - The English High Court recently dismissed the Bayer pharmaceutical company’s challenge against a regional clinical commissioning group’s policy allowing NHS Trusts to use a cheaper, but unlicensed, alternative to a sight preserving eye treatment. This makes sober reading for companies marketing “on-label” sales of medicines which are more expensive than off-label or unlicensed alternatives. Unsurprisingly, Bayer has sought to appeal the judgement. The Court has also created legal uncertainty for the NHS: the test for lawfulness is shifted from the Clinical Commission Groups and their policies to individual trusts which must ensure that every unlicensed use is lawful. This could generate legal action against NHS Trusts and ironically drive up costs for the public purse. What is clear is that the Court’s conclusions were heavily influenced by fiscal constraints which it accepted as a legitimate counterweight to the commercial interests of pharmaceutical companies. It also appears to establish in law the duty for doctors to have concern for the wider societal costs of prescribed treatments. This article summarises this complex judgement and offers advice for navigating the increasing focus on limited budgets, both for companies and physicians.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85057529616&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30498264

U2 - 10.1038/s41433-018-0280-3

DO - 10.1038/s41433-018-0280-3

M3 - Article

JO - Eye (Basingstoke)

JF - Eye (Basingstoke)

SN - 0950-222X

ER -